• Home
  • About
    • Executive Management
    • Board of Directors
    • Investors
    • Scientific Advisory Boards
    • Fact sheet
  • Products / R&D
    • Products
    • Pipeline
  • Media
  • Career
  • Contact us

Nuron Biotech

Nuron Biotech is developing novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases. Our team of industry veterans is advancing products that meet unmet medical needs for patients around the globe. Our lead drug candidate, RELONSIV™ (interferon beta-1b) is a new chemical entity currently in Phase 3 for patients with multiple sclerosis. Nuron’s vaccine brands include Meningitec™ and HibTITER®.

Recent Press Releases
Apr 22, 2013 :

Nuron Biotech to Present at BIO Business Forum®

Apr 02, 2013 :

Nuron Biotech Selected to Present at Future Leaders in the Biotech Industry Conference

Mar18, 2013 :

Nuron Biotech Receives Pennsylvania Bio’s 2013 Deal of the Year Award for Advancing Bioscience Industry

Dec 20, 2012 :

Nuron Biotech Raises $80 Million from HealthCare Royalty Partners

Dec 10, 2012 :

Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec™ from Pfizer

Nov 13, 2012 :

Nuron Biotech Completes Enrollment of a Pivotal Phase 3 Study for Proprietary Recombinant Human Interferon Beta-1b (NU100) in Relapsing Remitting Multiple Sclerosis

Apr 09, 2012 :

Nuron Biotech Expands Portfolio with Exclusive, Worldwide License for an Amyloid Beta 42 DNA Vaccine Candidate for Alzheimer's Disease

Recent News and Events
Jan. 11, 2013 :

Nuron Biotech CEO Dr. Shankar Musunuri interviewed on Executive Leaders Radio

Oct 14, 2012 :

Nuron Biotech VP Regulatory Affairs, Dr. Vijay Tammara received "Regulatory Science Achievement Award" at AAPS Annual Meeting and Exposition

Mar 22, 2012 :

Nuron Biotech CEO Dr. Shankar Musunuri interviewed with CEO IntroNet
  • Contact Us |
  • Career |
  • Sitemap |
  • Terms of Use
© 2008– 2012 Nuron Biotech, Inc. All Rights Reserved.